Preliminary safety findings: IFN-free DAA comb. with dasabuvir in chronic HCV patients

Preliminary data from an ongoing study revealed today at The International Liver Congress 2015 suggest that a combination of three direct-acting antivirals (DAAs) plus dasabuvir is well tolerated in patients with severe renal impairment or end-stage renal disease when used either with or without ribavirin. In addition, the combination led to rapid hepatitis C viral load suppression with no virological failures seen in the preliminary data from the ongoing open-label study.

In the study, treatment naïve non-cirrhotic adults with chronic HCV GT1 infection and (CKD) classified as stage 4 or stage 5, received 12 weeks of treatment with ombitasvir / paritaprevir / ritonavir and dasabuvir (3D) either with or without ribavirin. There was a 24-week post-treatment follow-up period. As of February 18 2015, 17 of a planned 20 patients in Cohort 1 had received treatment and six had completed treatment. The combination has been well tolerated to date, with no treatment-related serious adverse events, one hemoglobin decline to <8 g/dL, and no premature discontinuations of DAAs.

Limited data are available on the safety for treating hepatitis C infection (HCV) in patients with severe or end-stage and many of these patients currently go untreated and are vulnerable to disease progression.


Explore further

Daclatasvir-sofosbuvir combination highly effective and well tolerated in patients with hepatitis C

More information: SAFETY OF OMBITASVIR/PARITAPREVIR/RITONAVIR PLUS DASABUVIR FOR TREATING HCV GT1 INFECTION IN PATIENTS WITH SEVERE RENAL IMPAIRMENT OR END-STAGE RENAL DISEASE: THE RUBY-I STUDY, The International Liver Congress 2015
Provided by European Association for the Study of the Liver
Citation: Preliminary safety findings: IFN-free DAA comb. with dasabuvir in chronic HCV patients (2015, April 25) retrieved 28 October 2020 from https://medicalxpress.com/news/2015-04-prelim-safety-ifn-free-daa-dasabuvir.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
24 shares

Feedback to editors

User comments